Cited 75 times in
Everolimus-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis : The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장양수 | - |
dc.date.accessioned | 2014-12-19T16:59:54Z | - |
dc.date.available | 2014-12-19T16:59:54Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1936-8798 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90587 | - |
dc.description.abstract | OBJECTIVES: This study sought to evaluate the safety and efficacy of second-generation drug-eluting stents (DES) for patients with unprotected left main coronary artery (ULMCA) stenosis. BACKGROUND: The clinical benefit of second-generation DES for ULMCA stenosis has not been determined. METHODS: The authors assessed 334 consecutive patients who received everolimus-eluting stents (EES) for ULMCA stenosis between 2009 and 2010. The 18-month incidence rates of major adverse cardiac or cerebrovascular events (MACCE), including death, myocardial infarction (MI), stroke, or ischemia-driven target vessel revascularization (TVR), were compared with those of a randomized study comparing patients who received sirolimus-eluting stents (SES) (n = 327) or coronary artery bypass grafts (CABG) (n = 272). RESULTS: EES (8.9%) showed a comparable incidence of MACCE as SES (10.8%; adjusted hazard ratio [aHR] of EES: 0.84; 95% confidence interval [CI]: 0.51 to 1.40; p = 0.51) and CABG (6.7%, aHR of EES: 1.40; 95% CI: 0.78 to 2.54; p = 0.26). The composite incidence of death, MI, or stroke also did not differ among patients receiving EES (3.3%), SES (3.7%; aHR of EES: 0.63; 95% CI: 0.27 to 1.47; p = 0.29), and CABG (4.8%; aHR of EES: 0.67; 95% CI: 0.29 to 1.54; p = 0.34). However, the incidence of ischemia-driven TVR in the EES group (6.5%) was higher than in the CABG group (2.6%, aHR of EES: 2.77; 95% CI: 1.17 to 6.58; p = 0.02), but comparable to SES (8.2%, aHR of EES: 1.14; 95% CI: 0.64 to 2.06; p = 0.65). Angiographic restenosis rates were similar in the SES and EES groups (13.8% vs. 9.2%, p = 0.16). CONCLUSIONS: Second-generation EES had a similar 18-month risk of MACCE for ULMCA stenosis as first-generation SES or CABG. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | JACC-CARDIOVASCULAR INTERVENTIONS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Confidence Intervals | - |
dc.subject.MESH | Coronary Artery Bypass | - |
dc.subject.MESH | Coronary Restenosis/drug therapy* | - |
dc.subject.MESH | Coronary Restenosis/surgery | - |
dc.subject.MESH | Coronary Restenosis/therapy | - |
dc.subject.MESH | Coronary Vessels/pathology | - |
dc.subject.MESH | Drug-Eluting Stents* | - |
dc.subject.MESH | Everolimus | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents/administration & dosage | - |
dc.subject.MESH | Immunosuppressive Agents/therapeutic use* | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Risk | - |
dc.subject.MESH | Sirolimus/administration & dosage | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Sirolimus/therapeutic use* | - |
dc.title | Everolimus-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis : The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Young-Hak Kim | - |
dc.contributor.googleauthor | Duk-Woo Park | - |
dc.contributor.googleauthor | Jung-Min Ahn | - |
dc.contributor.googleauthor | Sung-Cheol Yun | - |
dc.contributor.googleauthor | Hae Geun Song | - |
dc.contributor.googleauthor | Jong-Young Lee | - |
dc.contributor.googleauthor | Won-Jang Kim | - |
dc.contributor.googleauthor | Soo-Jin Kang | - |
dc.contributor.googleauthor | Seung-Whan Lee | - |
dc.contributor.googleauthor | Cheol Whan Lee | - |
dc.contributor.googleauthor | Seong-Wook Park | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Myung-Ho Jeong | - |
dc.contributor.googleauthor | Hyo-Soo Kim | - |
dc.contributor.googleauthor | Seung-Ho Hur | - |
dc.contributor.googleauthor | Seung-Woon Rha | - |
dc.contributor.googleauthor | Do-Sun Lim | - |
dc.contributor.googleauthor | Sung-Ho Her | - |
dc.contributor.googleauthor | Ki Bae Seung | - |
dc.contributor.googleauthor | In-Whan Seong | - |
dc.contributor.googleauthor | Seung-Jung Park | - |
dc.identifier.doi | 10.1016/j.jcin.2012.05.002 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03448 | - |
dc.relation.journalcode | J01193 | - |
dc.identifier.eissn | 1876-7605 | - |
dc.identifier.pmid | 22814775 | - |
dc.subject.keyword | bypass surgery | - |
dc.subject.keyword | coronary disease | - |
dc.subject.keyword | left main coronary disease | - |
dc.subject.keyword | stents | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.affiliatedAuthor | Jang, Yang Soo | - |
dc.citation.volume | 5 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 708 | - |
dc.citation.endPage | 717 | - |
dc.identifier.bibliographicCitation | JACC-CARDIOVASCULAR INTERVENTIONS, Vol.5(7) : 708-717, 2012 | - |
dc.identifier.rimsid | 32852 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.